Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Aug
12
Today In Oncology
Global Survey Identifies Barriers to Integrative Oncology Use in Cancer Care
AI Biomarker May Guide Adjuvant Chemotherapy in Resected Pancreatic Cancer
First-in-Class Bispecific ADC Shows Activity in Relapsed Extensive-Stage Small Cell Lung Cancer
NIH-Funded International Research Yields Patient-Derived Tumor Compendium
Stanford Appoints New Leader to Expand Impact in Early Drug Development
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo